Merck Sharp + Dohme Corp.

Schering Corporation

Walter and Eliza Hall Institute of Medical Research

Msd R&d (China) Co., Ltd.

Idenix Pharmaceuticals, Inc.

Pharmacopeia Drug Discovery, Inc.

Schering-Plough Corporation

Scheeing Corporation

Merch Sharpe & Dohme LLC

Pharmacopeia Inc.

Msd R&d Co., Ltd.

Manuel De Lera Ruiz

Kevin D McCormick

Robert G Aslanian

Michael Berlin

Christopher W Boyce

Junying Zheng

Younong Yu

Rongze Kuang

Pietro Mangiaracina

Jianhua Chao

Neng-Yang Shih

Pauline C Ting

Daniel M Solomon

Mwangi W Mutahi

Xiaohong Zhu

Salem Fevrier

Jie Wu

Anandan Palani

Xianhai Huang

Purakkattle J Biju

Wing C Tom

Ashwin Umesh Rao

Walter Won

Chia-Yu Huang

Henry A Vaccaro

Bo Liang

Ning Shao

Li Dong

Bin Hu

Stuart B Rosenblum

John A McCauley

David Brian Olsen

Michael Man-Chu Lo

Zhuyan Guo

Izzat Tiedje Raheem

Timothy J Henderson

Yeon-Hee Lim

Michael J Kelly, Iii

Heping Wu

Ruiyan Liu

Rong-qiang Liu

Lisa Guise-Zawacki

Zhiyu Lei

Dongmei Zhan

Lianyun Zhao

Brad Sleebs

Andrew William Stamford

Amjad Ali

John D Schreier

Dong Xiao

Michael T Rudd

Shawn P Walsh

Harold B Wood

Dongfang Meng

Tao Yu

Richard Berger

Paul Tempest

Jayaram R Tagat

Wei Zhou

Tanweer A Khan

Yonglian Zhang

Jiayi Xu

Jean-Laurent Paparin

Timothy John Hartingh

Brent Whitehead

Dann LeRoy Parker, Jr

Hong Li

Ting Zhang

Gang Zhou

Robert Kevin Orr

Edward Metzger

Bart Harper

Jianhua Cao

Meng Yang

Tianying Jian

Jae-Hun Kim

Joe F Lee

Gioconda V Gallo

Jane Yang Wu

Louis-Charles Campeau

Sylvia Joanna Degrado

Sunita V Dewnani

Chander Shekher Celly

Liwu Hong

Alan F Cowman

Stephanie Louise Ciesla

Youngong Yu

Ali Amjad

David Won-Shik Kim

Alexander L Tung

Dong Won-Shik Kim

Paola Favuzza

Yushi Xiao

Jennifer K Thompson

Tony Triglia

Cailing Zhang

John A Mccauley

Michael J Kelly Iii

Methods of treating malaria comprising administration of compounds of Formula (I') or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. It also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin X, plasmepsin IX or plasmepsin X and IX activity, for treating ainfection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

Antimalarial agents

The present invention provides methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. The invention also provides uses of the compounds of Formula (I), as defined herein, for the possible inhibition of plasmepsin X, plasmepsin IX or plasmepsin X and IX activity, for treating ainfection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

Compounds of Formula I: I and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.

Phosphinic amide prodrugs of tenofovir

Compounds of Formula I: and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines. 

Antiviral benzyl-amine phosphodiamide compounds

The present invention is directed to 2,2-difluorodioxolo compounds that are antagonists of Areceptor. The present invention is also directed to uses of the 2,2-difluorodioxolo compounds described herein in the potential treatment or prevention of neurological disorders and diseases in which Areceptor are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds and to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which Areceptors are involved.

2,2-difluorodioxolo Areceptor antagonists

The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors. 

Factor IXa inhibitors

The present invention is directed to compounds of generic formula I: or pharmaceutically acceptable salts thereof that are believed to be useful as an A2A-receptor antagonist. 

[object Object]

In its many embodiments, the present invention provides a novel class of biaryl spiroaminooxazoline analogues as modulators of &#x3b1;2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the &#x3b1;2C adrenergic receptors using such compounds or pharmaceutical compositions.

Biaryl-spiroaminooxzaoline analogues as alpha 2C adrenergic receptor modulators

In its many embodiments, the present invention provides a novel class of biaryl compounds as inhibitors of &#xff;2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the &#xff;2C adrenergic receptors using such compounds or pharmaceutical compositions.

Functionally selective alpha2C adrenoreceptor agonists

Biaryl spiroaminooxazoline analogues as Alpha2C adrenergic receptor modulators

In its many embodiments, the present invention provides a novel class of biaryi spiroaminooxazoline analogues as modulators of &#x3b1;2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the &#x3b1;2C adrenergic receptors using such compounds or pharmaceutical compositions.

Biaryl-spiroaminooxazoline analogues as alpha 2C adrenergic receptor modulators

In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as &#x3b1;2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the &#x3b1;2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.

ALPHA2C adrenoreceptor agonists

Disclosed are compounds of the formula or a pharmaceutically acceptable salt thereof, wherein Mis N; X is a bond, optionally substituted alkylene, alkenylene, &#x2014;O&#x2014;, &#x2014;CHN(R)&#x2014;, &#x2014;N(R)CH&#x2014;, &#x2014;N(R)&#x2014;, &#x2014;NHC(O)&#x2014;, &#x2014;OCH&#x2014;, &#x2014;CHO&#x2014;, or &#x2014;S(O)&#x2014;; and Y is &#x2014;(CH)&#x2014;, &#x2014;C(&#x2550;O)&#x2014;, &#x2014;C(&#x2550;NOR)&#x2014; or &#x2014;SO&#x2014;;

Substituted aniline derivatives useful as histamine H3 antagonists

Disclosed are novel compounds of the formula or a pharmaceutically acceptable salt thereof, wherein: 

&#x3b1;2C adrenoreceptor agonists

Growing community of inventors

Branchburg, NJ, United States of America

Manuel De Lera Ruiz